Pancreatic cancer is one of the most lethal solid organ tumors. Due to the rising incidence,
late diagnosis, and limited treatment options, it is expected to be the second leading cause …

Pancreatic cancer is expected to be the second deadliest malignancy in the USA by 2020.
The survival rates for patients with other gastrointestinal malignancies have increased …

Abstract Background KRAS p. G12C mutation occurs in approximately 1 to 2% of pancreatic
cancers. The safety and efficacy of sotorasib, a KRAS G12C inhibitor, in previously treated …

Pancreatic cancer is the fourth leading cause of cancer-related death among men and
women in the United States. A major challenge in treatment remains patients' advanced …

Background Nanoliposomal irinotecan showed activity in a phase 2 study in patients with
metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based …

Purpose To assess the efficacy of a second-line regimen of oxaliplatin and folinic acid–
modulated fluorouracil in patients with advanced pancreatic cancer who have experienced …

Irinotecan is a topoisomerase inhibitor, widely used in treatment of malignancies including
pancreatic ductal adenocarcinoma (PDAC) as part of the FOLFIRINOX regimen prescribed …

Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer-related
deaths. PDAC remains one of the most difficult-to-treat cancers, owing to its unique …

Background This document is a summary of the French intergroup guidelines regarding the
management of pancreatic adenocarcinoma (PA), updated in July 2018. Design This …

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pancreatic
Adenocarcinoma discuss the workup and management of tumors of the exocrine pancreas …